Published in Eur J Cancer Clin Oncol on April 01, 1986
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest (1996) 1.44
TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis (2007) 1.08
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer (1987) 1.06
Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res (2001) 0.98
Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis (1998) 0.81
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis (1998) 0.79
Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study. Ann Rheum Dis (1992) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Nomogram for derivation of renal threshold phosphate concentration. Lancet (1975) 3.20
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 2.40
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 2.23
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 2.02
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet (1987) 1.90
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol (1992) 1.79
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 1.78
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet (1984) 1.77
Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet (1968) 1.77
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Testing of anti-human lymphocyte sera in chimpanzees and lower primates. Lancet (1968) 1.55
Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res (1987) 1.55
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol (2000) 1.51
Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review. Eur J Cancer (1993) 1.49
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
The assessment of phosphate reabsorption. Clin Chim Acta (1969) 1.42
[Coma due to an overdose of valnoctamide]. Ned Tijdschr Geneeskd (1992) 1.41
Primary extrauterine müllerian adenosarcoma of the peritoneum. Gynecol Oncol (1995) 1.41
[Consensus conference on osteoporosis]. Ned Tijdschr Geneeskd (1986) 1.39
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol (1987) 1.34
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner (1987) 1.31
Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer (1995) 1.30
Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev (1997) 1.23
Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res (1988) 1.22
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Natriuretic effect of calcitonin in man. N Engl J Med (1971) 1.21
Oestrogen receptor in human breast cancer tissue and response to endocrine therapy. Br Med J (1973) 1.21
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida. Infect Immun (1987) 1.19
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res (1990) 1.17
Complete remission at laparotomy: still a gold standard in ovarian cancer? Lancet (1986) 1.16
Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer (2004) 1.16
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol (1989) 1.16
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2002) 1.16
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Plasma-prolactin in human breast cancer. Lancet (1974) 1.15
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol (1999) 1.13
ras oncogene activation in human ovarian carcinoma. Oncogene (1988) 1.13
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med (1987) 1.13
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol (1986) 1.10
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol (2001) 1.09
Immunologic, virologic, and genetic aspects of mammary tumor virus-induced cell-surface antigens: presence of these antigens and the Thy 1.2 antigen on murine mammary gland and tumor cells. J Natl Cancer Inst (1975) 1.08
[Palliative treatment of intestinal obstruction in patients with cancer]. Ned Tijdschr Geneeskd (1993) 1.07
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06
Paget's bone disease treated with diphosphonate and calcitonin. Lancet (1976) 1.05
Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol (1989) 1.04
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol (1984) 1.03
Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci (1969) 1.02
Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol (1993) 1.01
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol (1987) 1.01
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1986) 1.01
Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol (1998) 1.00
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer (2005) 0.99
Bone scintigraphy and radiology in Paget's disease of bone: a review. Am J Physiol Imaging (1988) 0.99
cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res (1988) 0.99
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest (1982) 0.98
Metabolism of the coagulation factors of the prothrombin complex in hypothyroidism in man. Thromb Haemost (1979) 0.97
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol (1995) 0.97
Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther (2000) 0.97
Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer (1984) 0.96
Spontaneous hypoglycaemia in chronic renal failure. Neth J Med (1996) 0.96
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol (1995) 0.96
Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds. Am J Hum Genet (1993) 0.96
Immunohistochemical localization and chromatographic characterization of human chorionic gonadotropin in a bladder carcinoma. Arch Pathol Lab Med (1985) 0.95
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner (1986) 0.94
Relation between signs and symptoms in Paget's disease of bone. Q J Med (1986) 0.93
Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med (1980) 0.93